Skip to main content
. Author manuscript; available in PMC: 2011 Aug 1.
Published in final edited form as: Gynecol Oncol. 2010 May 8;118(2):182–188. doi: 10.1016/j.ygyno.2010.03.020

Figure 5.

Figure 5

Antitumor activity of MTM-SDK and MTM-SK in subcutaneous ovarian tumor xenograft. Mice (10 per group) were inoculated with A2780 cells and treated with 600 μg/Kg, q2d ×10, or vehicle (DMSO) given by intraperitoneal injections over a 20-day period. (A) Tumor size was measured twice weekly. Results are expressed as mean ± SD of 10 mice. Difference in tumor size is statistically significant after 10 days of treatment (** P <0.05). (B) Body weight was measured twice weekly. Data are presented as relative body weight, i.e., the difference between mean body weight at start of the treatment and at the indicated time points.